We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Application of Pegvisomant and Octreotide in Acromegaly

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00595140
First Posted: January 16, 2008
Last Update Posted: April 1, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ludwig-Maximilians - University of Munich
  Purpose
The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.

Condition Intervention Phase
Acromegaly Drug: pegvisomant Drug: combination with somatostatin analogue octreotide Drug: combination with dopamine agonist cabergoline Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment

Resource links provided by NLM:


Further study details as provided by Ludwig-Maximilians - University of Munich:

Primary Outcome Measures:
  • The decrease of endogenous growth hormone [ Time Frame: 6 or 9 hours ]

Secondary Outcome Measures:
  • The course of glucose, insulin and pegvisomant during the profiles [ Time Frame: 6 or 9 hours ]

Enrollment: 10
Study Start Date: January 2008
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: 1
patients with acromegaly on stable pegvisomant therapy
Drug: pegvisomant
growth hormone receptor antagonist pegvisomant in patients´ individual dose
Other Names:
  • Pegvisomant:
  • SOMAVERT 10 mg: EU/1/02/240/001
  • SOMAVERT 15 mg: EU/1/02/240/002
  • SOMAVERT 20 mg: EU/1/02/240/003
  • SOMAVERT 20 mg: EU/1/02/240/004
Active Comparator: 2
Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
Drug: combination with somatostatin analogue octreotide
s.c., 100µg, one time
Other Name: Octreotide: Sandostatin 100µg: MA number 29423.01.00
Active Comparator: 3
Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
Drug: combination with dopamine agonist cabergoline
oral, 0.5mg, one time
Other Name: Cabergoline: Dostinex 0.5mg: MA number 32411.00.00

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with acromegaly currently on stable pegvisomant therapy
  • patients with diabetes mellitus may be included. Glucose levels must be controlled regularly throughout the study
  • patients must not be co-treated with any other medication for acromegaly

Exclusion Criteria:

  • radiotherapy within the last 2 years
  • any relevant acute disease
  • history of hypersensitivity against any of the used drugs
  • pregnancy or lactation
  • abnormal baseline findings
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00595140


Locations
Germany
Medizinische Klinik - Innenstadt of the University of Munich
Munich, Germany, 80336
Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
Investigators
Principal Investigator: Jochen Schopohl, MD Medizinische Klinik - Innenstadt
  More Information

Responsible Party: PD Dr. Jochen Schopohl, Medizinische Klinik - Innenstadt of the University of Munich
ClinicalTrials.gov Identifier: NCT00595140     History of Changes
Other Study ID Numbers: EudraCT-Nr. 2007-005585-12
First Submitted: January 7, 2008
First Posted: January 16, 2008
Last Update Posted: April 1, 2008
Last Verified: January 2008

Keywords provided by Ludwig-Maximilians - University of Munich:
Acromegaly,
growth hormone receptor antagonist,
somatostatin analogue,
combined medical treatment,
acute effect,
endogenous GH

Additional relevant MeSH terms:
Acromegaly
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Dopamine
Cabergoline
Octreotide
Somatostatin
Dopamine Agonists
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists